LSE - Delayed Quote GBp

Advanced Oncotherapy plc (AVO.L)

1.9250 0.0000 (0.00%)
At close: August 30 at 4:23 PM GMT+1
Loading Chart for AVO.L
DELL
  • Previous Close 1.9250
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0870
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 10.445M
  • Beta (5Y Monthly) 0.07
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date Feb 13, 2024 - Feb 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

www.avoplc.com

174

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AVO.L

Performance Overview: AVO.L

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVO.L
9,900.00%
FTSE 100
2.10%

1-Year Return

AVO.L
6,900.00%
FTSE 100
0.17%

3-Year Return

AVO.L
393.59%
FTSE 100
12.48%

5-Year Return

AVO.L
327.78%
FTSE 100
5.84%

Compare To: AVO.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AVO.L

Valuation Measures

As of 4/19/2024
  • Market Cap

    10.44M

  • Enterprise Value

    67.68M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.17

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -2.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -11.73%

  • Return on Equity (ttm)

    -67.34%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -32.6M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.51M

  • Total Debt/Equity (mrq)

    98.71%

  • Levered Free Cash Flow (ttm)

    -34.96M